Overview

A Study of Evacetrapib in High-Risk Vascular Disease

Status:
Terminated
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
The Cleveland Clinic
Treatments:
Evacetrapib